Francine presently spearheads the IND-enabling initiative at ProteinQure, focusing on advancing the lead asset PQ203, a peptide drug conjugate, through the developmental pipeline. Previously, she made significant contributions at Northern Biologics, a clinical-stage biotechnology firm specializing in cancer immunotherapies, where she contributed to the advancement of their lead asset through Phase 2 clinical trials. Francine completed her PhD at the University of Toronto and conducted her postdoctoral training at Harvard Medical School.
Listed skills include Organic Synthesis, Protein Characterization, Protein Chemistry, Chemical Kinetics, and 27 others.